药明康德投出一家创新药IPO，6亿幽门螺杆菌感染者在等待，来自江苏苏州

Core Viewpoint - The article discusses the IPO of a company backed by WuXi AppTec, focusing on the potential market for innovative drugs targeting Helicobacter pylori infections, which affect approximately 600 million people globally [1] Company Summary - The company is based in Suzhou, Jiangsu, and is involved in the development of innovative drugs specifically for Helicobacter pylori infections [1] - The backing from WuXi AppTec indicates strong industry support and potential for successful market entry [1] Industry Summary - Helicobacter pylori infections are a significant global health issue, with an estimated 600 million infected individuals, highlighting a substantial market opportunity for new treatments [1] - The article emphasizes the growing demand for innovative therapies in the pharmaceutical industry, particularly in the area of infectious diseases [1]